The Journal of Rheumatology最新文献

Arthritis Mutilans in Psoriatic Arthritis: The Consequences of Delayed Treatment.

The Journal of Rheumatology Pub Date : 2025-04-15 DOI: 10.3899/jrheum.2025-0012

Deepti Agarwal,Kavita Krishna

引用次数: 0

Revisiting Magnetic Resonance Imaging Structural Lesions in the Sacroiliac Joints.

The Journal of Rheumatology Pub Date : 2025-04-15 DOI: 10.3899/jrheum.2025-0274

Denis Poddubnyy

引用次数: 0

Acrocyanosis After Immunotherapy: Vasculitis or Vasculopathy? New Iatrogenic Disease Case Series From CanRIO.

The Journal of Rheumatology Pub Date : 2025-04-15 DOI: 10.3899/jrheum.2024-0486

Yuliya Lytvyn,Megan E Himmel,Carrie Ye,Shahin Jamal,Alexandra P Saltman,

引用次数: 0

Frailty and Associated Outcomes in Patients with Vasculitis.

The Journal of Rheumatology Pub Date : 2025-04-15 DOI: 10.3899/jrheum.2024-1079

Sebastian E Sattui,John Stadler,Renee L Borchin,Cristina Burroughs,Laura Gandolfo,David Cuthbertson,Christine Yeung,Kalen Larson,Peter A Merkel,Robert Spiera,

{"title":"Frailty and Associated Outcomes in Patients with Vasculitis.","authors":"Sebastian E Sattui,John Stadler,Renee L Borchin,Cristina Burroughs,Laura Gandolfo,David Cuthbertson,Christine Yeung,Kalen Larson,Peter A Merkel,Robert Spiera,","doi":"10.3899/jrheum.2024-1079","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1079","url":null,"abstract":"OBJECTIVETo describe the frequency and outcomes associated with self-reported frailty in patients with vasculitis.METHODSVascStrong is a longitudinal study utilizing the Vasculitis Patient-Powered Research Network, an internet-based cohort of patients with vasculitis. Data collected included patient global assessment (PGA) and several domains of the Patient-Reported Outcomes Measurement Information Systems (PROMIS). Frailty was measured at baseline and 1-year follow-up using the FRAIL scale, a 5 domain self-reported measure. Patients were classified as non-frail, pre-frail, and frail based on 0, 1-2, or ≥3 criteria, respectively. At follow-up, patients reported the occurrence over the prior year of hospitalizations, infections, fractures, and disease flares. A multivariable logistic regression was performed to identify factors associated with frailty.RESULTSThe baseline survey included 328 patients. Patients had a mean age of 59.5 years, were predominantly female (71.6%) and non-Hispanic white. Prevalence of pre-frailty and frailty was 42.1% and 21.6%, respectively. The majority of patients with each form of vasculitis were classified as frail or pre-frail. Pre-frail and frail patients reported worse PROMIS scores at baseline and follow-up. Frailty was independently associated with female sex, higher PGA scores, being overweight, and obesity, but not with age. At 1-year, 272/328 (82.9%) patients answered the follow-up survey. Transitions in frailty status were observed in 99 (36.4%) patients. Hospitalizations and flares were more frequent in frail patients.CONCLUSIONSelf-reported frailty or pre-frailty is common in the majority of patients with multiple forms of vasculitis, indicating there is a substantial subset of patients at risk for worse outcomes.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patients' perspectives and experiences with medication for gout: A thematic synthesis of qualitative studies.

The Journal of Rheumatology Pub Date : 2025-04-15 DOI: 10.3899/jrheum.2024-1021

Olav Tvedten,Sacha Bossina,Muguet Koobasi,Allison Jaure,Brian Liang,Clarice Tang,Kathleen Tymms,Gabor Major,Ayano Kelly

引用次数: 0

Survival After Lung Transplantation in Patients With Rheumatoid Arthritis-Associated Lung Disease.

The Journal of Rheumatology Pub Date : 2025-04-15 DOI: 10.3899/jrheum.2025-0025

Amir A Razmjou,Angela Pham,Elizabeth R Volkmann,Veena K Ranganath

引用次数: 0

Effective treatment of Jak1/3 inhibitor in Blau syndrome from a multi-center retrospective study in central China.

The Journal of Rheumatology Pub Date : 2025-04-15 DOI: 10.3899/jrheum.2024-0822

Yangyang Hu,Pengcheng Li,Jinhua Liu,Zhipeng Zeng,Xiong Zhang,Wen Yin,Hai Xu,Jing Cai,Yikai Yu

{"title":"Effective treatment of Jak1/3 inhibitor in Blau syndrome from a multi-center retrospective study in central China.","authors":"Yangyang Hu,Pengcheng Li,Jinhua Liu,Zhipeng Zeng,Xiong Zhang,Wen Yin,Hai Xu,Jing Cai,Yikai Yu","doi":"10.3899/jrheum.2024-0822","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0822","url":null,"abstract":"OBJECTIVETo investigate the effectiveness of the JAK 1/3 inhibitor tofacitinib in treating Blau syndrome and explore the association between various clinical and genetic features and therapeutic responses within the cohort.METHODSA five-year, multi-center, retrospective, observational study was conducted across seven centers, focusing on genetic profiles and the clinical manifestations of cohort. Genetic analysis, including whole exome sequencing and NOD-2 and STAT3 rs2293152 phenotypic comparisons, was performed to assess therapeutic responses.RESULTSBaseline data for the cohort, with a median disease duration of 9.3 years. All patients exhibited arthritis, with 2 cases being oligoarticular and 22 polyarticular. The median joint count involved was 6, primarily affecting wrists, proximal interphalangeal joints, ankles, and knees. Radiographic analysis revealed symmetrical non-erosive arthropathy in 92.3% of patients. Notably, two-thirds of the cohort displayed previously unrecognized dysplastic bone changes. Ocular involvement was observed in all patients. Notably, no association was found between different NOD-2 sequences and therapy response. Conversely, patients harboring the STAT3 rs2293152 GG polymorphism demonstrated favorable responses treatment, regardless of whether JAK1/3 inhibitors or TNF-α inhibitors were used.CONCLUSIONTofacitinib could be an effective therapeutic option for BS patients who demonstrate resistance to TNF-α inhibitors or corticosteroids. Specifically, the STAT3 rs2293152 GG polymorphism was associated with improved response to treatment, suggesting a genotype-influenced therapeutic efficacy.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Canadian Rheumatology Association Guidance for Developing & Endorsing Quality Measures to Support Learning Health Systems.

The Journal of Rheumatology Pub Date : 2025-04-15 DOI: 10.3899/jrheum.2024-1065

Racheal Githumbi,Claire E H Barber,Susan J Bartlett,Karine Toupin-April,Marinka Twilt,Diane Lacaille,Cheryl Barnabe,Kiran Dhiman,Alison M Hoens,Adrian Grebowicz,Tara McMillan,Jessica Widdifield

{"title":"Canadian Rheumatology Association Guidance for Developing & Endorsing Quality Measures to Support Learning Health Systems.","authors":"Racheal Githumbi,Claire E H Barber,Susan J Bartlett,Karine Toupin-April,Marinka Twilt,Diane Lacaille,Cheryl Barnabe,Kiran Dhiman,Alison M Hoens,Adrian Grebowicz,Tara McMillan,Jessica Widdifield","doi":"10.3899/jrheum.2024-1065","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1065","url":null,"abstract":"OBJECTIVETo review methods for developing and endorsing Quality Measures (QMs) to inform a national quality measurement framework for rheumatology care in Canada.METHODSWe conducted a rapid environmental scan of measure development organizations from Canada, the United Kingdom, the United States and Australia. Major phases in the development of QMs were abstracted. The results were reviewed and synthesized with members of the Canadian Rheumatology Association's Digital Measurement Subcommittee through iterative review across 3 virtual meetings. The guidance was approved at the committee and the CRA board level.RESULTSFive key steps in the measure development cycle are proposed including: conceptualization and prioritization, measure specification development, testing and validation, implementation and reporting, continuous evaluation and maintenance. Foundational to all phases is the engagement of individuals from diverse backgrounds with lived experience of disease, healthcare providers, quality measurement scientists, and partner organizations. Measures should be aligned with domains of quality (effectiveness, efficiency, equity, patient-centeredness, safety and timeliness of care delivery) and be developed transparently. Endorsement of future QMs should, at minimum, prioritize validity, feasibility and acceptability or use/usability.CONCLUSIONThis paper establishes a comprehensive and relevant framework for the development and/or endorsement of QMs in Canadian rheumatology care. This framework will permit streamlining of future quality improvement efforts at the national level.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Update to a Systematic Review on Quality Measures for Rheumatoid Arthritis.

The Journal of Rheumatology Pub Date : 2025-04-15 DOI: 10.3899/jrheum.2024-1314

Racheal Githumbi,Steven J Katz,Jessica Widdifield,Claire E H Barber

{"title":"Update to a Systematic Review on Quality Measures for Rheumatoid Arthritis.","authors":"Racheal Githumbi,Steven J Katz,Jessica Widdifield,Claire E H Barber","doi":"10.3899/jrheum.2024-1314","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1314","url":null,"abstract":"OBJECTIVEThis work aims to provide an update on a previously published systematic review on quality measures (QMs) in rheumatoid arthritis (RA) to inform future measure development and endorsement efforts.METHODSWe searched published and grey literature sources from January 2018-July 2023. Included sources were limited to those that targeted RA patients, either exclusively or alongside other rheumatic conditions and were guided by a clear consensus-building methodology. We extracted QMs and categorized them into topic and subtopics. Extracted measures were then reviewed for similarity with the previously extracted set from a published systematic review. Non-duplicative measures were labelled as \"new\".RESULTSThe updated search resulted in 2395 citations from which 339 studies were selected for full text review. From these, a total of six studies met the inclusion/exclusion criteria resulting in the extraction of 156 QMs, along with 31 additional QMs extracted from 87 grey literature sources. Amongst the 187 extracted QMs, most were duplicative and/or similar to previously developed measures (68%, n= 127). 60 were identified as \"new\". New QMs were primarily structural (50%, n= 30) and process measures (33%, n= 20). New QMs frequently addressed the topic of health care delivery (35%, n= 21).CONCLUSIONWhile this review identified new QMs that reflect various reassuring trends in healthcare quality assessment, most were duplicative/similar to existing measures. This highlights the need for a centralized way to reduce redundancy in QM development efforts, and enable easy dissemination of QMs to optimize care for individuals with RA.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"218 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How Should We Count the Toe Joints in the 66/68 Joint Count in Psoriatic Arthritis? Results of an International Survey.

The Journal of Rheumatology Pub Date : 2025-04-15 DOI: 10.3899/jrheum.2025-0072

Gabriele De Marco,Helena Marzo-Ortega,Philip S Helliwell

引用次数: 0